SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001144204-13-015906
Filing Date
2013-03-18
Accepted
2013-03-18 17:09:55
Documents
9
Period of Report
2012-12-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-K v335724_10k.htm 10-K 1588733
2 EXHIBIT 21.1 v335724_ex21-1.htm EX-21.1 3173
3 EXHIBIT 23.1 v335724_ex23-1.htm EX-23.1 2682
4 EXHIBIT 24.1 v335724_ex24-1.htm EX-24.1 11887
5 EXHIBIT 31.1 v335724_ex31-1.htm EX-31.1 7959
6 EXHIBIT 31.2 v335724_ex31-2.htm EX-31.2 7931
7 EXHIBIT 32.1 v335724_ex32-1.htm EX-32.1 3742
8 EXHIBIT 32.2 v335724_ex32-2.htm EX-32.2 3823
9 GRAPHIC tpg2.jpg GRAPHIC 62498
  Complete submission text file 0001144204-13-015906.txt   1717297
Mailing Address 425 METRO PLACE NORTH SUITE 300 DUBLIN OH 43017
Business Address 425 METRO PLACE NORTH SUITE 300 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000810509 (see all company filings)

IRS No.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-35076 | Film No.: 13698830
SIC: 2835 In Vitro & In Vivo Diagnostic Substances